Quality of life during chemotherapy in lung cancer patients: Results across different treatment lines

British Journal of Cancer

Volumn 109, Issue 9, 2013, Pages 2301-2308

  Wintner, L M ^a   Giesinger, J M ^a   Zabernigg, A ^b   Sztankay, M ^a,c   Meraner, V ^a   Pall, G ^d   Hilbe, W ^d   Holzner, B ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

electronic patient reported outcome monitoring; lung cancer; multiple treatment lines; palliative chemotherapy; quality of life

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; COGNITION; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DYSPNEA; EMOTION; FATIGUE; FEMALE; HUMAN; LOSS OF APPETITE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTPATIENT CARE; PAIN; PALLIATIVE CHEMOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SLEEP DISORDER; SOCIAL INTERACTION;

EID: 84887017268     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.585     Document Type: Article

References (37)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5): 365-376.
2. Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362(10): 865-869.
3. Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D (2007a) Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc 14(3): 264-268.
4. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D (2007b) Long-Term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25(34): 5374-5380.
5. Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Fossella F (2006) Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 53(2): 231-239.
6. Bernhard J, Hurny C, Bacchi M, Joss RA, Cavalli F, Senn HJ, Leyvraz S, Stahel R, Ludwig C, Alberto P (1996) Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Br J Cancer 74(10): 1660-1667.
7. Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-Seymour M, Bush N, Karras BT, Lober WB, McCorkle R (2011) Enhancing patientprovider communication with the electronic self-report assessment for cancer: A randomized trial. J Clin Oncol 29(8): 1029-1035.
8. Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L, Shepherd FA (2008) Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10. J Clin Oncol 26(31): 5052-5059.
9. Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD (2005) Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 23(30): 7417-7427.
10. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374(9699): 1432-1440.
11. Claassens L, van Meerbeeck J, Coens C, Quinten C, Ghislain I, Sloan EK, Wang XS, Velikova G, Bottomley A (2011) Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 29(15): 2104-2120.
12. Damm K, Roeske N, Jacob C (2013) Health-related quality of life questionnaires in lung cancer trials: A systematic literature review. Health Econ Rev 3(1): 15.
13. Dancey J, Shepherd FA, Gralla RJ, Kim YS (2004) Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 43(2): 183-194.
14. Deshields TL, Potter P, Olsen S, Liu J, Dye L (2011) Documenting the symptom experience of cancer patients. J Support Oncol 9(6): 216-223.
15. Engelen V, Detmar S, Koopman H, Maurice-Stam H, Caron H, Hoogerbrugge P, Egeler RM, Kaspers G, Grootenhuis M (2012) Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: Is it effective?. Pediatr Blood Cancer 58(5): 766-774.
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917.
17. Gamper EM, Giesinger JM, Oberguggenberger A, Kemmler G, Wintner LM, Gattringer K, Sperner-Unterweger B, Holzner B, Zabernigg A (2012) Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: Prevalence, course of severity, and quality of life correlates. Acta Oncol 51(4): 490-496.
18. Gebbia V, Lorusso V, Galetta D, Caruso MM, Palomba G, Riccardi F, Borsellino N, Carrozza F, Leo S, Ferrau F, Cinieri S, Mancuso G, Mancarella S, Colucci G (2010) First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer 69(2): 218-224.
19. Gerber DE, Hamann HA, Rasco DW, Woodruff S, Lee SJ (2012) Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer. Patient Educ Counsel 89(1): 102-108.
20. Giesinger JM, Wintner LM, Oberguggenberger AS, Gamper EM, Fiegl M, Denz H, Kemmler G, Zabernigg A, Holzner B (2011) Quality of life trajectory in patients with advanced cancer during the last year of life. J Palliat Med 14(8): 904-912.
21. Hickish TF, Smith IE, O'Brien ME, Ashley S, Middleton G (1998) Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer 78(1): 28-33.
22. Lee LJ, Chung CW, Chang YY, Lee YC, Yang CH, Liou SH, Liu PH, Wang JD (2011) Comparison of the quality of life between patients with non-smallcell lung cancer and healthy controls. Qual Life Res 20(3): 415-423.
23. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24(34): 5441-5447.
24. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1): 139-144.
25. Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL (2008) Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manage Care 14(8): 530-539.
26. Park S, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ (2013) Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. Ann Oncol 24(6): 1630-1639.
27. Pat K, Dooms C, Vansteenkiste J (2008) Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: How CONSORTed are the datä Lung Cancer 62(1): 126-138.
28. Petrosyan F, Daw H, Haddad A, Spiro T (2012) Targeted therapy for lung cancer. Anticancer Drugs 23(10): 1016-1021.
29. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92(13): 1074-1080.
30. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10): 2095-2103.
31. Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ 317(7161): 771-775.
32. Snyder CF, Blackford AL, Wolff AC, Carducci MA, Herman JM, Wu AW (2013) Feasibility and value of PatientViewpoint: A web system for patient-reported outcomes assessment in clinical practice. Psychooncology 22(4): 895-901.
33. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20(5): 1335-1343.
34. Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C, Tombesi P, Lazzari-Agli L (2009) Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 135(6): 1596-1609.
35. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, Chu DT, Liao M, Chen YM, Kuo HP, Negoro S, Lam KC, Armour A, Magill P, Fukuoka M (2011) Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 6(11): 1872-1880.
36. Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans CE, Halyard MY, Revicki DA, Symonds T, Parada A, Alonso J (2008) The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature. Qual Life Res 17(2): 179-193.
37. Zabernigg A, Gamper EM, Giesinger JM, Rumpold G, Kemmler G, Gattringer K, Sperner-Unterweger B, Holzner B (2010) Taste alterations in cancer patients receiving chemotherapy: A neglected side effect?. Oncologist 15(8): 913-920.